The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 14; no. 8; p. 820
• Main Authors: Takács, Angéla, Szász, Zsófia, Kalabay, Márton, Bárány, Péter, Csámpai, Antal, Hegyesi, Hargita, Láng, Orsolya, Lajkó, Eszter, Kőhidai, László
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 20.08.2021; MDPI
• Subjects: antitumor efficacy; Apoptosis; bortezomib; Cancer; combination therapy; Cytotoxicity; Drug dosages; Experiments; Kinases; Ligands; Melanoma; Multiple myeloma; Proteins; TIC10
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph14080820

Combination antitumor treatments are essential parts of modern tumor therapy as—compared to monotherapies—(i) they are more effective; (ii) the dose of the compounds can be reduced; and (iii) therefore the side effects are improved. Our research group previously demonstrated the antitumor character of bortezomib (BOZ) in A2058 melanoma cells. Unfortunately, dose-related side effects are common during BOZ therapy, which could be prevented by reducing the dose of BOZ. This study aimed to characterize synergistic combinations of BOZ with a TRAIL (TNF-related apoptosis-inducing ligand) -inducing compound (TIC10), where the doses can be cut down but the efficacy is preserved. Endpoint cell viability assays were performed on A2058 cells, and synergism of BOZ and TIC10 was observed after 72 h. Synergism was further validated in a real-time impedimetric assay, and our results showed that BOZ-treated melanoma cells survived the treatment, an effect not registered in the co-treatments. Treatment with the combinations resulted in increased apoptosis, which was not accompanied by enhanced LDH release. Nevertheless, the expression of death receptor 5 (DR5) was increased on the cell surface without transcriptional regulation. In summary, our findings support the theory that the application of BOZ and TIC10 in combination could provide higher efficacy in vitro.